Blood dialyzer is a medical device used to remove excess waste and fluid from the blood of patients with kidney failure. The global blood dialyzer market is driven by the increasing prevalence of chronic kidney diseases and the growing geriatric population. Technological advancements in the field of blood dialysis and the rising demand for home dialysis treatments are also fueling market growth. Moreover, the growing demand for blood dialyzers in emerging economies and the increasing number of product launches and partnerships among key players are further contributing to market growth. However, the high cost of blood dialysis treatment and the risks associated with dialysis procedures may hinder market growth. Nonetheless, the increasing adoption of online hemodiafiltration (HDF) and the development of portable and wearable blood dialyzers are expected to offer significant growth opportunities in the blood dialyzer market.
Global Blood Dialyzer Market
size is valued at US$ 6,241.9 million in 2022 and is expected to witness a CAGR of 6.3% over the forecast period (2022 – 2030).
Leading Companies in the Blood Dialyzer Industry:
1. In 2021, Fresenius Medical Care AG & Co. KGaA announced that it is collaborating with Humacyte, Inc. to develop a blood dialyzer made from investigational human acellular vessels (HAVs). The companies plan to conduct a clinical study to assess the safety and efficacy of the blood dialyzer.
2. Baxter International, Inc. was founded in 1931 and is headquartered in Deerfield, Illinois, USA. The company operates in more than 100 countries and is a leading manufacturer of medical products and devices. In 2020, Baxter announced the launch of its new hemodialysis system, AK 98. The system is designed to provide better outcomes for patients with end-stage renal disease.
3. Nikkiso Co. Ltd. was founded in 1953 and is headquartered in Tokyo, Japan. The company operates in more than 13 countries and specializes in the manufacture of medical equipment, including blood dialyzers. In 2020, Nikkiso announced that it had received approval from the US Food and Drug Administration (FDA) for its DBB-06 dialyzer. The DBB-06 is a high-performance dialyzer designed to improve the clearance of small and middle molecules.
